(MENAFN- PR Newswire) DUBLIN, Oct. 17, 2022 /PRNewswire/ -- The report has been added to ResearchAndMarkets.com's offering.
The vaccine adjuvants market is projected to reach USD 16 Billion by 2027 from USD 1.5 Billion in 2022, at a CAGR of 1.7% during the forecast period.
The growth of the market is projected to be driven by factors such as the rising prevalence of infectious diseases, increasing number of COVID-19 vaccines in the development pipeline, and increasing focus on immunization programs.
The adjuvant emulsions accounted for the largest share of the product segment in the vaccine adjuvants market in 2021
Adjuvant emulsions function by generating depots that can trap antigens at the injection site. This results in slow release to continue the stimulation of the immune system. The adjuvant emulsions segment accounted for the largest share of the market in 2021. The extensive use of adjuvant emulsions in COVID-19 and other infectious diseases and the rising prevalence of infectious diseases are driving the growth of the adjuvant emulsions segment during the forecast period.
The infectious disease segment accounted for the largest share of the disease type segment in the vaccine adjuvants market in 2021
The infectious diseases segment accounted for the largest share of the market in 2021. The large share of this segment can be attributed to the increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines.
Key players in the vaccine adjuvants market include Prominent players in the global vaccine adjuvants market are GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivat? Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), and Vaxine Pty Ltd. (Australia).
Asia Pacific: The fastest-growing region in the vaccine adjuvants market
The Asia Pacific is estimated to be the fastest-growing segment of the market, owing to the increasing investments in the life sciences sector and rising awareness through conferences and symposiums. In this region, China and Japan are the largest markets while India is projected to grow at a highest CAGR during the forecast period.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights 4.1 Vaccine Adjuvants Market Overview4.2 North America: Vaccine Adjuvants Market, by Product and Country (2021)4.3 Vaccine Adjuvants Market Share, by Product, 2022 Vs. 20274.4 Vaccine Adjuvants Market: Geographic Growth Opportunities
5 Market Overview 5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Rising Prevalence of Infectious Diseases5.2.1.2 Increasing Use of Adjuvants in Vaccines5.2.1.3 Collaborations and Partnerships Among Market Players for Development of Vaccine Adjuvants5.2.1.4 Increasing Number of COVID-19 Vaccines in Development Pipeline5.2.1.5 Increasing Focus on Immunization Programs5.2.2 Restraints5.2.2.1 Skepticism About Animal-Sourced Vaccine Adjuvants and Limitations on Shark Fishing5.2.3 Opportunities5.2.3.1 Rising Funding for Vaccines and Infectious Disease Research Activities5.2.3.2 Development of Plant-Based Vaccine Adjuvants5.2.4 Challenges5.2.4.1 Side Effects and High Toxicity of Adjuvants5.3 Ranges/Scenarios5.4 Trends/Disruptions Impacting Customers' Businesses5.5 Pricing Analysis5.5.1 Average Selling Price of Products Offered by Market Players5.5.2 Average Selling Price Trend5.6 Technology Analysis5.6.1 Supercritical Fluid Extraction Technology5.7 Value Chain Analysis5.8 Ecosystem Analysis5.9 Patent Analysis5.10 Key Conferences and Events in 2022-20235.11 Regulatory Analysis5.11.1 Regulatory Bodies, Government Agencies, and Other Organizations in Different Regions/Countries5.12 Porter's Five Forces Analysis5.13 Key Stakeholders and Buying Criteria5.13.1 Key Stakeholders in Pharmaceutical and Biotechnology Companies and Their Influence on Buying Process5.13.2 Buying Criteria for Vaccine Adjuvants
6 Vaccine Adjuvants Market, by Product 6.1 Introduction6.2 Adjuvant Emulsions6.2.1 Adjuvant Emulsions Function by Generating Depots That Trap Antigens at Injection Site6.3 Pathogen Components6.3.1 Prominent Market Players Developing Bacteria-Derived Adjuvants - Key Factor Supporting Market Growth6.4 Saponin-Based Adjuvants6.4.1 Growing Demand for Saponin-Based Adjuvants to Drive Market6.5 Particulate Adjuvants6.5.1 Mineral-Based Adjuvants Most Widely Used Among Particulate Adjuvants6.6 Other Adjuvants
7 Vaccine Adjuvants Market, by Route of Administration 7.1 Introduction7.2 Intramuscular7.2.1 Largest and Fastest-Growing Market Segment7.3 Subcutaneous7.3.1 Advantages Offered by Subcutaneous Administration to Drive Market7.4 Other Routes of Administration
8 Vaccine Adjuvants Market, by Disease Type 8.1 Introduction8.2 Infectious Diseases8.2.1 Increased Prevalence of Infectious Diseases to Drive Market8.3 Cancer8.3.1 Increasing Demand for Novel Cancer Vaccines to Support Market Growth8.4 Other Diseases
9 Vaccine Adjuvants Market, by Application 9.1 Introduction9.2 Research Applications9.2.1 Extensive R&D for Development of Vaccine Adjuvants to Drive Market9.3 Commercial Applications9.3.1 Growing Use of Vaccine Adjuvants for Commercial Applications to Support Market Growth
10 Vaccine Adjuvants Market, by Application Category 10.1 Introduction10.2 Human Vaccine Adjuvants10.2.1 Increase in Partnerships for Development of Human Vaccine Adjuvants10.3 Veterinary Vaccine Adjuvants10.3.1 Development of Animal Vaccines Governed by Fewer Regulatory Aspects
11 Vaccine Adjuvants Market, by Region
12 Competitive Landscape 12.1 Introduction12.2 Right-To-Win Approaches Adopted by Key Players12.3 Market Share Analysis12.4 Revenue Analysis12.5 Company Evaluation Quadrant12.5.1 Stars12.5.2 Emerging Leaders12.5.3 Pervasive Players12.5.4 Participants12.6 Competitive Benchmarking of Top 25 Players12.6.1 Company Footprint (25 Companies)12.6.2 Company Product Footprint (25 Companies)12.6.3 Company Regional Footprint (25 Companies)12.7 Company Evaluation Quadrant for Startups/Smes12.7.1 Progressive Companies12.7.2 Starting Blocks12.7.3 Responsive Companies12.7.4 Dynamic Companies12.8 Competitive Benchmarking of Startup/Sme Players12.9 Competitive Scenario and Trends12.9.1 Product Launches12.9.2 Deals12.9.3 Other Key Developments
13 Company Profiles 13.1 Key Players13.1.1 Gsk plc13.1.2 Dynavax Technologies13.1.3 Novavax13.1.4 Agenus Inc.13.1.5 Croda International plc13.1.6 Seppic (Subsidiary of Air Liquide Group)13.1.7 Phibro Animal Health Corporation13.1.8 Spi Pharma (Subsidiary of Associated British Foods plc)13.1.9 Csl Limited13.1.10 Merck KGaA13.1.11 Oz Biosciences13.1.12 Invivogen13.1.13 Allergy Therapeutics13.1.14 Vertellus13.1.15 Eubiologics Co., Ltd.13.1.16 Pacific Genetech Limited13.1.17 Hawaii Biotech Inc.13.1.18 Riboxx GmbH13.1.19 Captivate Pharmaceuticals LLC13.1.20 Vaxine Pty Ltd.13.2 Other Companies13.2.1 Creative Diagnostics13.2.2 Litevax Bv13.2.3 Mukta Industries13.2.4 Oncovir, Inc.13.2.5 Titermax Usa, Inc.
14 Appendix
For more information about this report visit
Media Contact:
Research and MarketsLaura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904Fax (outside U.S.): +353-1-481-1716
Logo:
SOURCE Research and Markets
Comments
No comment